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Abstract: Alzheimer’s disease is a progressive, devastating, and irreversible brain disorder that, day
by day, destroys memory skills and social behavior. Despite this, the number of known genes suitable
for discriminating between AD patients is insufficient. Among the genes potentially involved in the
development of AD, there are the chitinase-like proteins (CLPs) CHI3L1, CHI3L2, and CHID1. The
genes of the first two have been extensively investigated while, on the contrary, little information is
available on CHID1. In this manuscript, we conducted transcriptome meta-analysis on an extensive
sample of brains of healthy control subjects (n = 1849) (NDHC) and brains of AD patients (n = 1170) in
order to demonstrate CHID1 involvement. Our analysis revealed an inverse correlation between the
brain CHID1 expression levels and the age of NDHC subjects. Significant differences were highlighted
comparing CHID1 expression of NDHC subjects and AD patients. Exclusive in AD patients, the
CHID1 expression levels were correlated positively to calcium-binding adapter molecule 1 (IBA1)
levels. Furthermore, both in NDHC and in AD patient’s brains, the CHID1 expression levels were
directly correlated with calbindin 1 (CALB1) and neurogranin (NRGN). According to brain regions,
correlation differences were shown between the expression levels of CHID1 in prefrontal, frontal,
occipital, cerebellum, temporal, and limbic system. Sex-related differences were only highlighted in
NDHC. CHID1 represents a new chitinase potentially involved in the principal processes underlying
Alzheimer’s disease.
Keywords: CHID1; Alzheimer’s disease; chitinases; bioinformatics
1. Introduction
Neurodegeneration indicates a progressive structural, functional, and molecular alter-
ation of neurons, with consequent progressive cell degeneration. As regards, neurodegener-
ative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease (AD), Parkinson’s
disease, and Huntington’s disease, they are characterized by neurodegenerative phenom-
ena [1]. The molecular mechanisms that regulate these diseases are also present in aging
and neurodegenerative diseases. The damage to neurons revealed during aging can be
considered to be exacerbated in neurodegenerative diseases [2]. The neurodegenerative
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processes are triggered by genetic predisposition factors linked to intrinsic susceptibility
and epigenetic mechanisms associated with environmental factors, with aging itself in-
creasing the risk [2]. Being able to understand the principal molecules that regulate the
cellular mechanisms of the neuroglia represents a new strategy to counteract the develop-
ment and progression of neurodegenerative diseases. Among the main neurodegenerative
diseases, Alzheimer’s disease (AD) represents one of the most common with still unknown
pathogenesis [3]. Recently, several investigations have demonstrated the decisive role
of both neuroinflammation and the toxicity carried out by amyloid-beta (Aβ) peptide
on central nervous system (CNS) neurons [4]. Aβ peptides tend to precipitate forming
microaggregates, commonly called “soluble Aβ oligomers”, protofibrils, and fibrils which
tend to accumulate in the brains of AD patients, forming the more well-known insoluble
“amyloid plaques” [5]. Consequently, the accumulation of Aβ peptides results in neuron
death and local immune activation, which leads to synaptic and cognitive dysfunctions.
Several proteins, such as chitinases [6], calcium-binding adapter molecule 1 (IBA1) [7],
platelet endothelial cell adhesion molecule (CD31) [8], and calbindin 1 (CALB1) [9], could
be considered new potential markers of the cellular architecture alteration of the nervous
system parenchyma.
Mammalian chitinases consisting of chitinase acid (CHIA) [10], chitotriosidase
(CHIT1) [11], chitinase 3-like protein 1 (CHI3L1) [12], chitinase 3-like protein 2 (CHI3L2) [13],
and chitinase domain-containing protein 1 (CHID1) [14] exert important biological roles in
different cell types, such as polarized macrophages [15], dendritic cells [16], osteoclasts [17],
and several cells with high proliferative activity [18,19]. CHI3L1, CHI3L2, and CHID1 are
chitin-binding proteins (CLPs) that lack chitin-hydrolyzing activity but possess cytokine-
like and growth factor-like properties. The expression of CLPs has been related to several
pathological phenomena with an inflammatory etiogenesis [20]. In recent years, different
roles have been attributed to CLPs, such as tissue remodeling during inflammation, dif-
ferentiation, and maturation of macrophages. Its high levels have been associated with
various pathological disorders such as diabetes [21], osteoarthritis [22], and asthma [23].
Very little is known about the role of CHID1, which is also known as stabilin-1-interacting
chitinase-like protein (SI-CLP). It has been shown that interact with the protein STAB1. The
protein structure presents carbohydrate binding sites, which could be involved in carbohy-
drate catabolysis. CHID1 is a marker for alternative macrophage activation. CHID1 was
abundantly detected in bronchoalveolar lavage from patients with chronic inflammatory
disorders of the respiratory tract and human peripheral blood leukocytes [24]. CHID1
secretion is mediated by its interaction with the endocytic/sorting receptor stabilin-1 and
is activated by Th2 cytokines [24]. Our recent papers detected the existence of CHID1
in pediatric brain tumors [14], macrophages infected with HIV-1 virus [25], and LOAD
brain patients [13,26]. Although CHID1 was initially associated with alternative activated
macrophages, evidence suggests that during neurodegenerative processes, its expression is
abundant in the nucleoplasm of microglia [27]. Currently, there is no exhaustive informa-
tion on its possible correlation with markers of neuroimmune activation, alteration of the
blood–brain barrier (BBB), and neuronal transmission. Starting from this data, we selected
IBA1, CD31, and CALB1, new neurodegeneration markers, in order to identify potential a
correlation with CHID1 in the CNS.
Allograft inflammatory factor 1 (AIF-1), also known as ionized calcium-binding
adapter molecule 1 (IBA1), is mainly produced by the innate immune cells specifically in
monocyte-derived macrophages [28], neutrophils [29], and microglia [30] in response to
the cytokine IFN-γ [31]. It has been shown to be overexpressed during the activation of the
immune cells in CNS injuries. As for its distinctive characteristics, it can be considered a
glia marker of activation [32]. Recently, it has been hypothesized that IBA1 can regulate
microgliosis by determining the scavenger of cellular debris, produced as waste during
neurodegenerative processes, the recruitment of oligodendrocytes, and the reorganization
of CNS cellular structure [33].
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Platelet endothelial cell adhesion molecule (PECAM-1) is also known as cluster of dif-
ferentiation 31 (CD31), highly expressed on neutrophils, monocytes, lymphocytes, platelets,
and endothelial cells [34]. It was demonstrated that it plays a role in cell adhesion by medi-
ating the diapedesis of the immune system cells through the modification of the vascular
wall, suggesting a role potential as a vascular integrity marker [34]. Currently, it has been
shown to have direct involvement in the regulation of BBB integrity [35]. Furthermore,
it has also been shown that CD31 plays a relevant role in Aβ-related cerebral vascular
disorders pathogenesis, such as AD [36], and is involved in the pathological molecular
mechanism of neurological disease and in neuroHIV neuroinflammation [37].
Calbindin 1 (CALB1) is a calcium-binding and buffering protein, and it has been
highlighted that it has a relevant role in preventing neuron death [38]. Alterations in
the expression levels of this gene have been highlighted in patients with Huntington’s
disease [39]. Due to its function, an increase in its expression has been associated with a
protective role in various neurological diseases. Actually, the increase in CALB1 protein
induces neurite outgrowth in dopaminergic neuronal cells and provides protection to
dopaminergic neurons against pathological processes in Parkinson’s disease [40]. With
aging, calbindin-containing neurons cells in the basal forebrain gradually die, and this
process is exacerbated in AD patients [41]. During human immunodeficiency virus en-
cephalitis (HIVE), neuronal damage could be produced by CALB1 reduction and increased
neuron intracellular calcium [42].
Neurogranin (NRGN or Ng) is a 78-amino-acid-long post-synaptic protein, highly
expressed in the brain, predominantly in dendritic spines of neurons in the amygdala,
hippocampus, cerebral cortex, and other associative cortical areas [43,44]. Its protein
actively participates in signal transduction in the protein kinase C signaling pathway. The
main function is carried out at a postsynaptic level, regulating the availability of calmodulin,
binding to it via an IQ motif (amino acid 33–46) in the absence of calcium. It has been
shown that the mRNA and protein levels in the hippocampus decrease with age and are
related to CNS dysfunction [45]. Its concentration in cerebrospinal fluid (CSF) is considered
an index of synaptic dysfunction in neurodegeneration. High levels have been shown
in the CSF of AD patients compared to healthy controls [46]. Data analysis from brain
tissue indicates a decrease of NRGN concentrations in both the frontal cortex [47], parietal
cortex [48], and hippocampus [47]. There is a direct link between NRGN and CHI3L1 so as
to be able to consider the two proteins of the independent markers of synaptic degeneration
and neuroinflammation in AD [49].
In this study, we investigated the expression levels of CHID1 in NDHCS subjects and
brain biopsies of AD patients, and the possible correlations with aging, in different brain
regions. To do this, we collected and clustered the transcriptome of more than 3000 brain
samples present in NCBI in the GEODataSet section. Furthermore, we hypothesized that
the CHID1 expression levels in the AD patient brain samples were correlated with markers
of microglial activation (IBA1), vascular integrity (CD31), and neuronal death (CALB1) and
neurogranin (NRGN), all phenomena characterizing the brain of AD patients.
2. Materials and Methods
2.1. Data Selection
For our analysis, we have collected 18 microarray datasets of brain data biopsies of non-
demented subjects who died from causes not attributable to neurodegenerative diseases,
and deceased patients suffering from AD. The transcriptome datasets were downloaded
from NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/
geo/, accessed on 9 January 2021) [50]. MeSH terms “Brain region”, “Human”, and
“Alzheimer’s disease” were used to identify human potential datasets of interest. The
selected datasets are shown in Table 1.
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Table 1. Datasets selected.
N◦ Dataset Organism Platform NDHC AD References
1 GSE33000 Homo sapiens GPL4372 HBTRC 144 310 [51]
2 GSE28894 Homo sapiens GPL6104 NIA 29 0 [52]
3 GSE35978 Homo sapiens GPL6244 SMRI 13 0 [53]
4 GSE15745 Homo sapiens GPL6104 UMBB 132 0 [54]
5 GSE44772 Homo sapiens GPL4372 HBTRC 273 387 [55]
6 GSE36192 Homo sapiens GPL6947 NIA 379 0 [56]
7 GSE60862 Homo sapiens GPL5175 UKBEC 226 0 [57]
8 GSE118553 Homo sapiens GPL10558 MRC-LBB 72 167 [58]
9 GSE25219 Homo sapiens GPL5175 BTBDDUM 27 0 [59]
10 GSE71620 Homo sapiens GPL11532 PBTDP 208 0 [60]
11 GSE5392 Homo sapiens GPL96 SMRIC 3 0 [61]
12 GSE36980 Homo sapiens GPL6244 KU 47 32 [62]
13 GSE26927 Homo sapiens GPL6255 BNEN 4 11 [63]
14 GSE84422 Homo sapiens GPL570 MSBB 28 74 [64]
15 GSE5281 Homo sapiens GPL570 ADCs 74 87 [65]
16 GSE48350 Homo sapiens GPL570 ADC 93 80 [66]
17 GSE11882 Homo sapiens GPL570 MSBB 93 0 [67]
18 GSE28146 Homo sapiens GPL570 BBADRCUK 8 22 [68]
Harvard Brain Tissue Resource Center (HBTRC); Mount Sinai Medical Center Brain
Bank (MSBB); National Institute on Aging (NIA); Stanley Medical Research Institute (SMRI);
University of Maryland Brain Bank (UMBB); UK Brain Expression Consortium (UKBEC);
Medical Research Council (MRC) London Neurodegenerative Diseases Brain Bank (from
now on referred to as MRC-LBB); University of Pittsburgh’s Brain Tissue Donation Program
(PBTDP); Neuropathology Consortium of the Stanley brain collection (Stanley Medical
Research Institute, US) (SMRIC); Kyushu University (KU); BrainNet Europe network
(BNEN); Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB); Alzheimer’s Disease
Centers (ADCs); Brain Bank of the Alzheimer’s Disease Research Center at the University
of Kentucky (BBADRCUK); Brain and Tissue Bank for Developmental Disorders at the
University of Maryland (BTBDDUM); NDHC = non-demented healthy controls subjects;
AD = Alzheimer’s disease patients.
Each brain with AD was age-matched to a healthy brain to rule out any differences due
to routine aging. Furthermore, we stratified the samples according to sex and age as shown
in Table 2. Five groups were obtained: middle-age (53–65 years), senior (66–75 years),
elderly (76–89 years), nonagenarian (90–99 years) and centenarian (>100 years) [12].
Table 2. Sample stratification.
Age Stage NDHCS AD
1 53–65 middle-age 734 = 582 male + 152 female 59 = 34 male + 25 female
2 65–75 senior 425 = 291 male + 134 female 219 = 75 male + 144 female
3 76–89 elderly 493 = 328 male + 165 female 639 = 361 male + 278 female
4 90–99 nonagenarian 179 = 61 male + 118 female 235 = 187 male + 48 female
5 >100 centenarian 22 = 4 male + 18 female 18 = 13 male + 5 female
Total sample 1853 1170
NDHC = non-demented healthy controls subjects; AD = Alzheimer’s disease patients.
All brains sample analyzed were grouped into 8 main brain regions (prefrontal, frontal,
occipital, cerebellum, temporal, cingulate, diencephalon, limbic system). Complete brain
regions details examined are presented in Table 3.
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Table 3. Brain regions analyzed.
N◦ Brain Regions Abbreviations Brain Portions n◦ of Sample Age
1 prefrontal PFC
prefrontal cortex; dorsolateral prefrontal
cortex; dorsolateral prefrontal cortex; medial
prefrontal cortex; ofc (orbitofrontal cortex);
orbitofrontal cortex; orbital prefrontal cortex;
ventral forebrain; ventrolateral cortex;
ventrolateral prefrontal cortex
1045 = 784 male +
261 female 51.18 ± 21
2 frontal FC frontal cortex frontal pole (Brodmann area9, 10); medial frontal cortex
868 = 577 male +
291 female 51.07 ± 26.08
3 occipital OC occipital cortex; primary visual cortex;visual cortex
286 = 207 male +
79 female 55.16 ± 25.44
4 cerebellum CB cerebellar cortex; cerebellum; upper (rostral)rhombic lip
1009 = 693 male +
316 female 50.9 ± 24.52
5 temporal TP
inferior temporal cortex; primary auditory
cortex; superior temporal cortex; superior
temporal cortex (Brodmann area 22); temporal
cortex; ventral head of the caudate nucleus
466 = 174 male +
292 female 47.77 ± 29.01
6 cingulate CYN
anterior cingulate; caudal ganglionic eminence;
lateral ganglionic eminence; medial ganglionic
eminence; medial temporal gyrus; postcentral
gyrus; posterior cingulate; posterior cingulate
cortex; subpial grey matter lesions from the
frontal gyri; superior frontal gyrus
319 = 196 male +
123 female 61.35 ± 22.55
7 diencephalon DIE
basal ganglia; dorsal thalamus; putamen;
striatum; nucleus accumbens; substantia nigra;
thalamus; mediodorsal nucleus of
the thalamus
450 = 304 male +
146 female 55.41 ± 24.47
8 limbic system LS amygdala; entorhinal cortex; hippocampus 563 = 356 male +207 female 56.83 ± 26.31
2.2. Clinical and Neuropathological Criteria
A total of 1853 data points from frozen tissue samples were selected belonging to sub-
jects who did not die from causes related to neurological diseases that we have identified
as non-demented healthy controls subjects (NDHC) (70.63 ± 12.45 years) and 1170 samples
taken from AD patients (82.03 ± 9.29 years). Most of the samples analyzed were obtained
from public brain databases (Table 1). Postmortem interval (PMI), sample pH, and RNA
integrity number (RIN) were elements of pre-selection by the authors of the reference
microarray datasets and, subsequently, were bases for further exclusion in our analysis.
For the diagnosis of AD, we took into consideration the investigations carried out by the
authors of the individual datasets (Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) guidelines, progressive decline in memory, cognitive deficits in two or
more areas, MMSE , CDR, Braak stage, general and regional atrophy, gray and white matter
atrophy, ventricular enlargement, and cataloged neuropathological diagnosis by patholo-
gists based on e.g., neurofibrillary tangle (NFT) counts). As regards the cognitive integrity
of the healthy subjects included in our analysis, we took into account the investigations and
cognitive tests carried out by the authors of the microarray datasets listed in Table 1 (mem-
ory complaints, history of memory complaints, normal cognitive function documented by
scoring age and education adjusted, mini-mental status examination (MMSE), and global
clinical dementia rating, CDR).
2.3. Data Processing and Experimental Design
In order to process and identify significantly differentially expressed genes (SDEG)
in all selected datasets, we used MultiExperiment Viewer (MeV) software (The Institute
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for Genomic Research (TIGR), J. Craig Venter Institute, USA). In cases where multiple
genes probes insisted on the same GeneID, we used those with the highest variance. The
significance threshold level for all datasets was p < 0.05. Statistically significant genes
were selected for further analysis. For all datasets we performed a statistical analysis with
GEO2R, applying a Benjamini and Hochberg FDR (false discovery rate) to adjust p values
for multiple comparisons [69–72].
2.4. Statistical Analysis
For statistical analysis, Prism 8.0.2 software (GraphPad Software, San Diego, CA,
USA) was used. Based on Shapiro–Wilk test, almost all data were normal, so parametric
tests were used. Significant differences between groups were assessed using the ordinary
one-way ANOVA test, and Tukey’s multiple comparisons test correction was performed to
compare data between all groups. Correlations were determined using Pearson correlation.
All tests were two-sided, and significance was determined at adjusted p value of 0.05.
All MD selected were transformed for the analysis in Z-score intensity signal. Z score
is constructed by taking the ratio of weighted mean difference and combined standard
deviation according to Box and Tiao (1992) [73]. The application of a classical method of
data normalization, z-score transformation, provides a way of standardizing data across a
wide range of experiments and allows the comparison of microarray data independent of
the original hybridization intensities. The z-score is considered a reliable procedure for this
type of analysis and can be considered a state-of-the-art method, as demonstrated by the
numerous articles [74–85].
The efficiency of each biomarker was assessed by the receiver operating characteristic
(ROC) curve analyses [86,87]. Nonparametric ROC curves analyzed AD vs. NDHC.
The area under the ROC curve (AUC) and its 95% confidence interval (95% CI) indicate
diagnostic efficiency. The accuracy of the test with the percent error is reported [88].
3. Results
3.1. Sex-Dependent Differences in CHID1 Brain Expression of NDHC Subjects and AD Patients
For our analysis, we have collected 1170 AD patients and 1849 non-demented healthy
control subjects (NDHC) in order to verify the CHID1 expression levels. The samples were
stratified into five groups according to age (middle-age, senior, elderly, nonagenarian, and
centenarian). A summary of sample sizes included in this study is described in Table 2.
Brain CHID1 RNA expression levels were significantly lower in patients with AD
as compared to NDHC subjects (Figure 1A,B). When comparing the whole-brain CHID1
expression levels of NDHC and AD according to the sex, we found no significant differ-
ence (Figure 1B).
There was a moderate inverse correlation between CHID1 brain expression levels in
NDHC and age (r = −0.1050, p < 0.0001) (Figure 2A). A significant inverse correlation in
CHID1 brain expression levels has been observed in both males (r = −1051, p = 0.0002)
(Figure 2B) and females (r = −1019, p = 0.0135) (Figure 2C) of NDHC subjects.
The correlation analysis between CHID1 expression levels and age in the brains of AD
patients showed conflicting results (Figure 3). Brain expression of CHID1 did not correlate
with age in AD patients (r = 0.050, p = ns) (Figure 3A). In AD male patients, we observed
the same trend for all samples (r = 0.082, p = ns) (Figure 3B), while in females, a positive
correlation with age was highlighted (r = 0.1501, p < 0.00001) (Figure 3C).
3.2. Neurodegeneration Markers Correlated with CHID1 Expression Levels in the CNS
In dividing the samples of the 1170 AD patients according to sex, 500 were males
and 670 were females, and of the 1849 NDHC subjects, 1264 were males and 585 were
females (Table 2). We sorted the samples according to gender and carried out a comparative
analysis of expression levels.
The analysis of 1849 NDHC brains show that the CHID1 expression levels were
correlated with CD31 (r = −0.061, p = 0.0082), CALB1 (r = 0.2671, p < 0.0001), and NRGN
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(r = −0.2538, p < 0.0001). No correlation was observed between CHID1 and IBA1 expression
levels (Figure 4A).
In the 1264 NDHC male brain samples, we showed that the CHID1 expression levels
were correlated with CD31 (r = −0.097, p = 0.0005), CALB1 (r = 0.2413, p < 0.0001), and
NRGN (r = 0.2661, p < 0.0001) (Figure 4B). In addition, for NDHC male brains, no correlation
was observed between CHID1 and IBA1.
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Figure 4. Correlation analysis betwe n rain CHID1 expression levels and neurological markers in
DHC subjects. Analysis of the c rrelation between the CHID1, IBA1, CD31, ALB1, and NRGN
expre sion levels in all brains (1853) (A), and in brains sort d according to 1266 males (B) an
587 f males (C) belonging to NDHC subjects. Data in the figure are in icated as z-score intensity
expression levels and presented graphically as dot plots. p values < 0.05 were considered to be
statistically significant.
When we analyzed the 585 NDHC female brain samples, we demonstrated that CHID1
expression levels correlated both to CALB1 (r = 0.3135, p < 0.0001) and to NRGN (r = 0.2237,
p < .0001), but not to CD31 (r = −0.009, p = ns) (Figure 4B). Contr ry to data highlighted
in the brains of NDHC males, CHID1 expression was negatively correlated with IBA1 in
females (r = −0.097, p = 0.0 84) (Figure 4C).
P rtially overlapping ults wer highlighted in AD brains. The analysis of 117 AD
brains show that CHID1 expression levels were correlated with IBA1 (r = 0.201 , p < 0.0 0 ),
CD31 (r= −0.09, p = 0.0019), CALB1 (r = 0.1249, p < 0.0001), and NRGN (r = 0.1544, p < 0.0001)
(Figur 5A).
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In analyzing the CHID1 expression level in the brains of 500 AD males, we have been
able to ascertain that its expression level were correlated with IBA1 (r = 0.1781, p < 0.0001),
CALB1 (r = 0.095, p =0.036), and NRGN (r = 0.1791, p < 0.00001) but not to CD31 (r = 0.081,
p = ns) (Figure 5B).
Regarding the 670 AD female brains, the results show that the CHID1 expression
levels correlated with IBA1 (r = 0.2172, p < 0.0001), CD31 (r= −0.09, p = 0.0098), CALB1
(r = 0.1474, p = 0.0001), and NRGN (r = 0.1414, p = 0.0002) (Figure 5C).
3.3. CHID1 Levels Are Differentially Expressed in Eight Brain Regions
We deepened our investigation by comparing the expression levels of CHID1 in the
different brain regions according to sex. Fifty-eight brain portions were grouped into 8 main
brain regions (prefrontal, frontal, occipital, cerebellum, temporal, cingulate, diencephalon,
and limbic system). Complete brain regions details examined in this paper are available
in Table 3.
In analyzing the NDHC subjects’ eight brain regions, we observed that the highest
CHID1 expression levels were in the occipital cortex, while the lowest were in the cingulate
cortex (Figure 6A). As regards the AD patients’ eight brain regions, we observed that the
highest CHID1 expression levels were in the diencephalon, while the lowest were in the
temporal cortex (Figure 6B). Significant differences in CHID1 expression levels were found
by comparing the frontal cortex (p < 0.0001, p = 0.001), prefrontal (p < 0.0001, p = 0.001),
occipital (p < 0.0001, p < 0.0001), (p = 0.001), and temporal (p < 0.0001, p < 0.001) brain
regions with the cingulate and limbic system in NDHC subjects (Figure 6A). Furthermore,
we observed that CHID1 expression in the cerebellum was significantly lower than in the
occipital lobe (p < 0.01) (Figure 6A).
As regards the AD patients’ brain regions, we observed significant differences in
CHID1 expression levels by comparing the cerebellum (p = 0.001), temporal (p < 0.0001),
cingulate (p = 0.001), occipital (p = 0.01), and prefrontal (p < 0.0001) brain regions with the
diencephalon (Figure 6B). Furthermore, we observed that CHID1 expression in the limbic
system was significantly lower than in the diencephalon (p < 0.001) (Figure 6B).
In analyzing the CHID1 expression levels in the eight brain regions in NDHC subjects
and AD patients, we highlighted a significant difference only in NDHC subjects’ limbic
system region, in which males had significantly lower levels than females (p < 0.0001)
(Figure S1A). No significant difference between the sexes was observed in the different
brain regions of AD patients (Figure S1B).
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Figure 6. CHID1 levels are differentially expressed in brain regions of NDHC subjects and AD
patients. Analyzing the NDHC in ividu l b ain regions, we observed that the highest CHID1
expre sion levels w re in the occipital cortex, whil the lowest in the region of cingulate (A). As
regards the AD patients’ brain regions, we observed that the highest CHID1 expression levels were
in the diencephalon, while the lowest at the region of the temporal cortex (B). See the text for details.
Data in the figure are indicated as z-score intensity expression levels and presented graphically as
violin dot plots. p values < 0.05 were considered to be statistically significant (ns = not significant;
+, * p < 0.01; §§, ##, ˆˆ, **, p < 0.001; ˆˆˆ, ççç, ###, p < 0.0001; ++++, ####, ˆˆˆˆ, ****, p < 0.00001).
By analyzing the individual brain regions according to the disease, we observed that
the CHID1 expression levels were significantly higher in NDHC than in AD in all brain
regions, with the exception of the diencephalon and cingulate regions (Figure 7).
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3.4. ROC Analysis Confirmed the Diagnostic Ability of CHID1 to Discriminate AD Patients from
NDHC Subjects
In order to evaluate the potential diagnostic ability of CHID1 to discriminate the AD
patients from NDHC subjects, we performed a receiver operating characteristic (ROC)
analysis. We showed that CHID1 express a fair diagnostic ability to discriminate the AD
from NDHC (AUC = 0.6368, p < 0.0001) (Figure 8A). This ability was maintained for both
males (AUC = 0.6440, p < 0.0001) (Figure 8B) and females (AUC = 0.6304, p < 0.0001)
(Figure 8C).
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Figure 8. CHID1 brain expression levels as a prognostic marker of AD. In order to evaluate the
potential diagnostic ability of CHID1 to discriminate against the AD patients from NDHC subjects,
we performed a receiver operating characteristic (ROC) analysis. CHID1 expressed fair diagnostic
ability (AUC = 0.6368, p < 0.0001) (A). This ability was maintained for both males (AUC = 0.6440,
p < .0001) (B) and females (AUC = 0.6304, p < 0.0001) (C).
4. Discussion
Here, we have shown that the gene expression of CHID1 was downregulated in
the brain of AD patients compared to NDHC subjects, and both in NDHC and in AD
patients, the expression levels were strongly correlated with NRGN and CALB1. Only in
AD patients, the CHID1 expression levels were positively correlated with IBA1 levels. A
closer investigation of the CHID1 expression levels in the different brain regions showed
significant correlation differences between NDHCS and AD in prefrontal, frontal, occipital,
cerebellum, temporal, and limbic system. Sex-related differences in CHID1 expression were
only highlighted in NDHC subjects’ limbic system region in which males had significantly
lower levels than females.
In recent years, the use of datasets available in public databases has grown expo-
nentially. Several research groups, including ours, have extensively used the analysis of
public transcriptome datasets for the identification of novel pathogenic pathways and ther-
apeutic targets in several human pathologies [25,26,89–94] including neurodegenerative
disease [6,12,13,25,95,96] and cancer [14,97–99]. Through a meta-analysis of public array
datasets, it is possible to increase the statistical power to obtain a more precise estimate of
gene expression differentials, and assess the heterogeneity of the overall estimate. Meta-
analysis is relatively inexpensive since it makes comprehensive use of already available
data and represents a vast source of information that could make a difference in setting up
highly targeted experimental strategies.
To date, information regarding the potential role played by CHID1 in CNS has re-
mained very poor. On the contrary, great attention has been paid to other chitinase-like
proteins such as CHI3L1, CHI3L2, CHIA, and CHIT1 and their role in various inflammatory
processes [100,101]. In 2016, our group demonstrated, for the first time, that the CHID1
expression levels were significantly downregulated in the brains of LOAD patients and
were not related to sex [13]. In this manuscript, we have shown that CHID1 expression
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levels were significantly downregulated in AD patients and correlated positively with
NRGN and CALB1 and negatively with IBA1 and CD31 in the brain of NDHC subjects.
Furthermore, in the 1266 brain sample biopsies of males and in the 587 of female
NDHC subjects, the CHID1 expression levels were inversely correlated with age. These
results are in line with the data previously observed by our group in a small cohort
of samples [13]. In the past, we have speculated that CHI3L1 could play a role in the
cytoskeletal structure [11,16]. Such data have also been partially verified for CHID1 [16].
Indeed, it has been shown that CHID1 suppressed macrophage cytoskeletal rearrangements
in response to CCL2 [102]. Furthermore, using the online tool “The Human Protein
Atlas”, we have observed that CHID1 protein was localized in the nucleoplasm and in
intermediate filaments. This potential interaction with the cytoskeleton could partially
explain the inverse correlation with age as well as the reduction in the brain in AD subjects.
Numerous studies analyzing human postmortem tissue, animal models, and cellular
paradigms indicate that AD pathology has a deleterious effect on the pathways governing
actin cytoskeleton stability [103]. These conditions have also been demonstrated during
brain aging [104]. It is known that the cytoskeleton is an abundant and broadly expressed
structure that plays critical functions in many cellular processes ranging from cell motility
to controlling cell shape and polarity. In light of this, cytoskeleton function in neurons is
crucial for the morphological changes that occur in the brain throughout life. We could
hypothesize that the CHID1 expression is linked to the cytoskeleton and that it can play a
role at the level of the dendritic spines. The cytoskeleton alteration mediated by CHID1
could be one of the key events contributing to the initial phases of aging in the brain or
during the AD progression. Furthermore, we showed that both in males and females during
aging, in healthy subjects and in AD patients, the expression levels of CHID1 and NRGN
were closely related. There is a close relationship between NRGN and rearrangement
of the cytoskeletal structures of neurons [105]. It is known that NRGN is a postsynaptic
protein primarily expressed in the brain, particularly in dendritic spines. Because of its
abundant and preferential neuronal expression, NRGN has been identified as a potential
marker of age-related neurodegeneration. Synaptic loss is an early pathologic substrate
of AD. Actually, the CSF protein levels are used as AD progression markers [106]. The
strong correlation identified between CHID1 and NRGN brain expression levels allows us
to hypothesize a probable common role between the two genes.
An extremely interesting result highlighted during our investigation was the strong
correlation between CHID1 and CALB1 expression levels in the brain of NDHC subjects and
AD patients. CALB1 is one of the major calcium-binding proteins that plays a critical role
in preventing neuronal death as well as maintaining calcium homeostasis [41]. Decreased
CALB1 expression levels represent an index of neuronal death. It has been shown that
CALB1 removal from amyloid precursor protein/presenilin transgenic mice aggravates
AD pathogenesis, suggesting that CALB1 has a critical role in AD pathogenesis [41]. The
fact that the CHID1 and CALB1 expression levels are strongly correlated suggests not only
that CHID1 is localized at the level of neurons but that it can play a role in structural
maintenance. Other chitinases have already shown multifaceted functions according to the
cells in which they are expressed. CHID1 could also perform different functions depending
on the cellular environment in which it is expressed. Not surprisingly, in our analysis, we
have observed a positive correlation between the expression levels of CHID1 and IBA1 only
and exclusively at the level of the brains of AD patients, regardless of gender. This would
suggest that CHID1 could be also associated with microglial activation. The association
between CHID1 and macrophage lineage activation represents one of the few pieces of
information currently available on the role played by this gene [25].
CHID1 brain expression levels were different in the eight brain regions analyzed.
In NDHC subjects, the highest levels were in the occipital lobe, a region involved in
functions linked to visual perception, while the lowest were in the cingulate cortex, a
region involved in certain higher-level functions such as attention allocation, decision-
making, morality, impulse control, and emotion. In the brains of AD patients, this trend
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was completely distorted, finding the lowest levels in the temporal region involved in
processing sensory input visual memory and comprehension of language, and the highest
levels in the diencephalon, which includes several regions with functions associated with
recognition of the sensory impulses of heat, cold, pain, pressure, control of eye movement,
and hearing responses.
Sex differences in CHID1 expression levels were observed only in the limbic system
region in NDHC subjects, in which males had significantly lower levels than females. These
results would suggest that CHID1 could play different roles in healthy subjects compared
to AD patients, and that its function could be potentially related to the cognitive functions
of the brain regions to in which it is involved.
Summing up, our analysis shows that CHID1 has an opposite trend in the CNS
compared to other CLPs. Indeed, while the levels of CHI3L1 and CHI3L2 in AD patients
tend to increase leading to hypothesis of a potential immunological role, CHID1 levels tend
to decrease both with age and in neurological diseases such as AD. This reduction associated
with both physiological and pathological aging as in AD could suggest a structural, rather
than immunological, role in the neurons.
5. Conclusions
The biological function of CHID1 remains poorly explored and still unknown. Our
manuscript has tried to partially shed light on the potential involvement of its expres-
sion in AD disease. Previously, our group identified three other chitinases involved in
AD [13,107,108]. While the CHIT1, CHI3L1, and CHI3L2 expression levels tend to increase
in the brain of AD patients, most likely because they are linked to neuroinflammation and
innate immune cell activation, in the opposite manner, the CHID1 levels tend to decrease,
and we hypothesized this is because they are linked to neuron death. A therapeutic strat-
egy that significantly reduces the neuroinflammation in the brain of AD patients could
consequently be reflected as a reduction in the expression levels of CHIT1, CHI3L1, and
CHI3L2. Regarding the CHID1 expression levels, therapy capable of reducing or slowing
neuronal death could be verified by an increase in CHID1 expression levels. Most likely,
the action of CHID1 inside neurons is attributable to structural, cytoskeletal functions, but
further studies are needed to prove this hypothesis. We recently hypothesized that the role
of CHID1 can be also involve the nuclear level [16].
In light of this information, the sexual differences in the CHI3L1 and CHI3L2 expres-
sion levels, highlighted in e recent papers [13] and also partially found for CHID1, could
open the door to targeted strategies involving gender-specific therapies. Unfortunately, as
for the differential diagnosis, we cannot answer exhaustively if CHID1 is a unique marker
of AD disease, but it represents an excellent starting point for further investigations in order
to investigate the potential role of CHID1 in the diagnosis and progression of this disease.
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